Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remikiren
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Remikiren is an orally active small molecule renin inhibitor developed for the treatment of hypertension and heart failure. It acts by specifically inhibiting human renin (IC50 ≈ 0.7 nM), thereby blocking the conversion of angiotensinogen to angiotensin I in the renin-angiotensin system, which leads to a reduction in blood pressure. Remikiren was first developed by Hoffmann–La Roche and demonstrated potent antihypertensive effects in preclinical and clinical studies; however, its development was discontinued before approval[1][2][3][4][5][6][7].
- Other names
- remikiren
02
Targets
REN (Renin)
Beyond the preview
Go deeper on remikiren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remikiren.